Holdings
Eaton Vance Worldwide Health Sciences Fund
As of May 31, 2026, Eaton Vance Worldwide Health Sciences Fund reported 41 positions worth US$753M. Largest: Eli Lilly and Company, AbbVie Inc. and Johnson & Johnson. What it bought and sold, with each filing.
Holdings
- Positions
- 41
- Value as reported
- US$753M
- Holdings as of
- May 31, 2026
- Last filed
- Jul 27, 2026
| Company | Shares | Value as reported | % of portfolio | Change | As of |
|---|---|---|---|---|---|
| Eli Lilly and Company NYSE:LLY | 85,543 | US$94.5M | 12.5% | −6,863 | May 31, 2026 |
| AbbVie Inc. NYSE:ABBV | 225K | US$48.9M | 6.5% | −21,559 | May 31, 2026 |
| Johnson & Johnson NYSE:JNJ | 217K | US$48.9M | 6.4% | No change | May 31, 2026 |
| AstraZeneca PLC LSE:AZN | 255K | US$47.3M | 6.2% | −11,968 | May 31, 2026 |
| UnitedHealth Group Incorporated NYSE:UNH | 109K | US$41.6M | 5.5% | No change | May 31, 2026 |
| Roche Holding Ltd SIX:RO | 98,026 | US$41.2M | 5.4% | −27,800 | May 31, 2026 |
| Merck & Company, Inc. NYSE:MRK | 324K | US$38.5M | 5.1% | +16,988 | May 31, 2026 |
| Bristol-Myers Squibb Company NYSE:BMY | 564K | US$32.2M | 4.3% | No change | May 31, 2026 |
| Vertex Pharmaceuticals Incorporated NASDAQ:VRTX | 57,284 | US$25.6M | 3.4% | −3,396 | May 31, 2026 |
| Gilead Sciences, Inc. NASDAQ:GILD | 188K | US$25.3M | 3.3% | No change | May 31, 2026 |
| Sanofi SA EURONEXT:SAN | 255K | US$22.3M | 2.9% | No change | May 31, 2026 |
| Thermo Fisher Scientific Inc NYSE:TMO | 42,998 | US$21.2M | 2.8% | −4,192 | May 31, 2026 |
| Intuitive Surgical, Inc. NASDAQ:ISRG | 48,480 | US$20.6M | 2.7% | No change | May 31, 2026 |
| Stryker Corporation NYSE:SYK | 54,948 | US$16.8M | 2.2% | No change | May 31, 2026 |
| Boston Scientific Corporation NYSE:BSX | 341K | US$16.5M | 2.2% | +47,110 | May 31, 2026 |
| Medtronic plc. NYSE:MDT | 185K | US$13.7M | 1.8% | No change | May 31, 2026 |
| Lonza Group AG SIX:LONN | 21,010 | US$13.4M | 1.8% | −974 | May 31, 2026 |
| Novo Nordisk A/S Class B OMXCOP:NOVO_B | 284K | US$13M | 1.7% | No change | May 31, 2026 |
| Abbott Laboratories NYSE:ABT | 146K | US$12.5M | 1.7% | −90,441 | May 31, 2026 |
| Novartis AG SIX:NOVN | 83,123 | US$12.5M | 1.6% | +13,094 | May 31, 2026 |
| argenx SE EURONEXT:ARGX | 14,601 | US$12.2M | 1.6% | −2,942 | May 31, 2026 |
| Royalty Pharma plc NASDAQ:RPRX | 215K | US$12M | 1.6% | No change | May 31, 2026 |
| Neurocrine Biosciences, Inc. NASDAQ:NBIX | 67,430 | US$10.7M | 1.4% | +15,776 | May 31, 2026 |
| Mettler-Toledo International, Inc. NYSE:MTD | 8,731 | US$10.3M | 1.4% | No change | May 31, 2026 |
| Straumann Holding AG SIX:STMN | 83,976 | US$10.1M | 1.3% | No change | May 31, 2026 |
| Quest Diagnostics Incorporated NYSE:DGX | 50,412 | US$9.83M | 1.3% | New | May 31, 2026 |
| Genmab A/S OMXCOP:GMAB | 34,565 | US$9.06M | 1.2% | +17,875 | May 31, 2026 |
| Edwards Lifesciences Corporation NYSE:EW | 103K | US$8.87M | 1.2% | −43,738 | May 31, 2026 |
| Zoetis Inc. NYSE:ZTS | 109K | US$8.5M | 1.1% | −91,247 | May 31, 2026 |
| The Cooper Companies, Inc. NASDAQ:COO | 128K | US$7.85M | 1.0% | No change | May 31, 2026 |
| CSL Limited ASX:CSL | 99,071 | US$6.88M | 0.91% | −35,091 | May 31, 2026 |
| Heartflow, Inc. NASDAQ:HTFL | 219K | US$6.78M | 0.90% | No change | May 31, 2026 |
| Danaher Corporation NYSE:DHR | 37,052 | US$6.77M | 0.89% | No change | May 31, 2026 |
| Recordati S.p.A. MIL:REC | 91,672 | US$5.51M | 0.73% | No change | May 31, 2026 |
| Xenon Pharmaceuticals Inc. NASDAQ:XENE | 100K | US$5.48M | 0.72% | +48,772 | May 31, 2026 |
| Generate Biomedicines, Inc. NASDAQ:GENB | 313K | US$4.1M | 0.54% | New | May 31, 2026 |
| Apogee Therapeutics, Inc. NASDAQ:APGE | 33,655 | US$2.76M | 0.36% | No change | May 31, 2026 |
| NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 81,652 | US$2.75M | 0.36% | No change | May 31, 2026 |
| Caris Life Sciences, Inc. NASDAQ:CAI | 136K | US$2.27M | 0.30% | No change | May 31, 2026 |
| EssilorLuxottica SA EURONEXT:EL | 10,648 | US$2.15M | 0.28% | No change | May 31, 2026 |
| MBX Biosciences, Inc. NASDAQ:MBX | 59,688 | US$1.88M | 0.25% | New | May 31, 2026 |